Pharma Equity Group AS (OCSE:PEG) ROE % Adjusted to Book Value: -22.02% (As of Dec. 2025)


What is Pharma Equity Group AS ROE % Adjusted to Book Value?

Pharma Equity Group AS OCSE:PEG -0.72% ROE % Adjusted to Book Value is -22.02% as of Dec. 2025. The stock has 3 warning signs investors should review.

Pharma Equity Group AS's ROE % for the quarter that ended in Dec. 2025 was -97.99%. Pharma Equity Group AS's PB Ratio for the quarter that ended in Dec. 2025 was 4.45. Pharma Equity Group AS's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -22.02%.

Pharma Equity Group AS ROE % Adjusted to Book Value Related Terms

Pharma Equity Group AS ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Pharma Equity Group AS's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Equity Group AS ROE % Adjusted to Book Value Chart

Pharma Equity Group AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.63 -57.62 -3.97 -19.88 -19.61

Pharma Equity Group AS Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.01 -8.51 -26.87 -13.83 -22.02

OCSE:PEG vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Pharma Equity Group AS's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharma Equity Group AS ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group AS's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group AS's ROE % Adjusted to Book Value falls into.


Pharma Equity Group AS ROE % Adjusted to Book Value Calculation

Pharma Equity Group AS's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-87.28% / 4.45
=-19.61%

Pharma Equity Group AS's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-97.99% / 4.45
=-22.02%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -22.02% mean?
Pharma Equity Group AS (OCSE:PEG) has a ROE % Adjusted to Book Value of -22.02% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Pharma Equity Group AS and its competitors.
Is Pharma Equity Group AS's ROE % Adjusted to Book Value too high?
Pharma Equity Group AS's current ROE % Adjusted to Book Value is -22.02%.
How does Pharma Equity Group AS's ROE % Adjusted to Book Value compare to VRTX and REGN?
Pharma Equity Group AS's ROE % Adjusted to Book Value of -22.02% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Pharma Equity Group AS and its competitors. Pharma Equity Group AS's current ROE % Adjusted to Book Value is -22.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Equity Group AS stock overvalued right now?
Pharma Equity Group AS (OCSE:PEG) has a current ROE % Adjusted to Book Value of -22.02%. The current ROE % Adjusted to Book Value is -22.02%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Pharma Equity Group AS (OCSE:PEG), the current ROE % Adjusted to Book Value is -22.02% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharma Equity Group AS Business Description

Address Slotsmarken 12, 1.th, Horsholm, DNK, DK-2970
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .